Passer au contenu principal

Luigina Mollica

Mollica, Luigina

Assistant clinical professor

Affiliation

Université de Montréal

Research Axes

Immunology-oncology

Contact information

Phone: 514-252-3400, poste3404

lmollica.hmr@ssss.gouv.qc.ca

A hematologist and medical oncologist, Dr. Luigina Mollica also has a PhD in gene regulation and pathology. Dr. Mollica heads the Transcriptional Regulation of Gene Expression Research Unit. A specialist in lymphoproliferative syndromes, she is also an assistant clinical professor in the Faculty of Medicine at Université de Montréal.

At Hôpital Maisonneuve-Rosemont, she oversees clinical research in hematology and medical oncology, the hematology sector of the Molecular Biology Laboratory, and the Department of Hematology, Oncology and Transplantation. She is actively involved with the specialized clinic on multiple myeloma and is the co-investigator of clinical studies on this disease with the Université de Montréal Myeloma Canada Chair on Multiple Myeloma at Hôpital Maisonneuve-Rosemont. Dr. Mollica is a fellow of the Royal College of Physicians of Canada in internal medicine, hematology and medical oncology. Dr. Mollica is also the assistant director for clinical research at the CIUSSS de l’Est-de-l’Île-de-Montréal.

Research Unit

Transcriptional Regulation of Gene Expression

Research interests

  • Transcriptional regulation of gene expression
  • Aging of the hematopoietic system
  • Cancer immunotherapy
  • Chronic myeloid leukemia and other myeloproliferative neoplasms
  • Lymphomas and other lymphoproliferative disorders
  • Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Ozcan M, Kosinova M, Bouabdallah K, Morschauser F, Stevens DA, Giurescu M, Cupit L, Liu L, Kochert K, Seidel H, Pena C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphadidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. Journal of Clinical Oncology 2017;35:3898-3905.
    More detail
  • Buscarlet M, Provost S, Zada YF, Barhadadi A, Bourgoin V, Mollica L, Szuber N, Dubé MP, Busque L. DNMT3 and TET2 dominate age-associated clonal hematopoiesis, have benign hematological phenotypes but different genetic predisposition. Blood 2017;130:753-762.
  • Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group. Early switch to second-line tyrosine kinase inihibitor in chronic myeloid leukemia patients failing to achieve early molecular response. American Journal Hematology 2017;92:602-604.
    More detail
  • Buscarlet M, Tessier A, Provost S, Mollica L, Busque L. Human blood cell levels of 5-hydroxymethycytosine (5hmC) decline with age, partly related to acquired mutations in TET2. Journal of Experimental Haematology, 2016:44:1072-1084.
    More detail
  • Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L. Reversible lymph node follicular hyperplasia associated with dasatinib treatment for chronic myeloid leukaemia in chronic phase. Blood 2013;122: 3082-3084.
    More detail
  • Busque L, Patel JP, Figueroa M, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi, M, Socci N, Gonen M, Mason CE, Melnick A, Godley LA, Brennan C, Abdel-Wahab O, Levine RL. Somatic Mutations are recurrent in normal elderly individuals with clonal hematopoiesis. Nature Genetics 2012;44:1179-1181.
  • Bernard L, Belisle C, Mollica L, Provost S, Roy DC, Gilliland DG, Levine RL, and Busque L. Telomere length is severely and similarly reduced in JAK2V617F positive and negative myeloproliferative neoplasms. Leukemia 2009;23:287-291.
    More detail
  • Mollica L, Fleury I, Belisle C, Provost S, Roy DC, and Busque L. No association between telomere length and blood cell counts. J Gerontol A Biol Sci Med Sci 2009;64:965-967.
  • Busque L, Paquette Y, Mollica L, Roy DC, Levine RL, and Gilliland DG. To be skewed or not to be? This is no longer the question. Blood 2009;114:2358-2359.
  • Busque L, Paquette Y, Provost S, Roy DC, Levine RL, Mollica L, Gilliland DG. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood 2009;113:3472-3474.
    More detail

Education

  • Doctor of medicine

    Université de Montréal

  • Specialty in internal medicine

    Université de Montréal

  • Specialty in hematology

    Université de Montréal

  • Specialty in medical oncology

    Université de Montréal

  • MSc in molecular biology

    Imperial College London, United Kingdom

  • PhD in pathology

    University of London, United Kingdom

Awards

  • 2007 New Clinician Researcher Award  (Université de Montréal)
  • 2005 Young investigator award  (International Society of Thrombosis and Haemostasis (ISTH) British Society for Haemostasis and Thrombosis (BSHT))
  • 2004 Young investigator award  (University of London (UK))